Patents by Inventor Lufen Chang

Lufen Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9770473
    Abstract: Disclosed are methods of using blastomere-like stem cells to decrease a level of myeloid-derived suppressor cells (MDSCs). A method for decreasing a level of myeloid-derived suppressor cells (MDSCs) in a human subject, including: injectionally, orally or transdermally administering to the human subject an amount of human blastomere-like stem cells, autologous to the human subject, at 1×108 to 1×1011 cells each time once every two weeks, for example.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: September 26, 2017
    Assignee: StemBios Technologies, Inc.
    Inventors: James Wang, Yun Yen, Lufen Chang
  • Publication number: 20140030237
    Abstract: Disclosed are methods of using blastomere-like stem cells to treat a number of immunodeficiency disorders.
    Type: Application
    Filed: October 4, 2013
    Publication date: January 30, 2014
    Applicant: StemBios Technologies, Inc.
    Inventors: James Wang, Yun Yen, Lufen Chang
  • Patent number: 8563307
    Abstract: Disclosed are methods of using blastomere-like stem cells to (1) decrease the level of myeloid-derived suppressor cells, (2) modulate immune response, (3) overcome a myeloid-derived suppressor cell-mediated immunosuppression, and (4) treat a cellular proliferative disorder. The blastomere-like stem cells, positive for CD66e, can be isolated from blood, bone marrow, or skeletal muscle.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: October 22, 2013
    Inventors: James Wang, Lufen Chang, Yun Yen
  • Publication number: 20100215622
    Abstract: Disclosed are methods of using blastomere-like stem cells to treat a number of immunodeficiency disorders.
    Type: Application
    Filed: February 24, 2009
    Publication date: August 26, 2010
    Applicant: California Cancer Institute
    Inventors: James Wang, Lufen Chang, Yun Yen
  • Publication number: 20070207137
    Abstract: A method of treating a metabolic disorder associated with insulin resistance by administering to a mammal an inhibitor of a NH2-terminal Jun Kinase (JNK), e.g., a compound or peptide which inhibits JNK1 expression or enzymatic activity.
    Type: Application
    Filed: May 1, 2007
    Publication date: September 6, 2007
    Applicant: Harvard University, President and Fellows of Harvard College
    Inventors: Gokhan Hotamisligil, Michael Karin, Lufen Chang
  • Patent number: 7232897
    Abstract: Disclosed herein are compositions and methods used to modulate a NH2-terminal Jun Kinase activity. These compositions and methods can be employed to regulate metabolic disorders associated with, for example, insulin such as diabetes. The reduction in NH2-terminal Jun Kinase activity can lead to the reduction in weight and improve insulin sensitivity.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: June 19, 2007
    Assignee: Harvard University, President and Fellows of Harvard College
    Inventors: Gokhan S. Hotamisligil, Michael Karin, Lufen Chang
  • Publication number: 20050261247
    Abstract: Disclosed herein are compositions and methods used to modulate a NH2-terminal Jun Kinase activity. These compositions and methods can be employed to regulate metabolic disorders associated with, for example, insulin such as diabetes. The reduction in NH2-terminal Jun Kinase activity can lead to the reduction in weight and improve insulin sensitivity.
    Type: Application
    Filed: April 24, 2002
    Publication date: November 24, 2005
    Inventors: Gokhan Hotamisligil, Michael Karin, Lufen Chang